Pulmonary Disease Examination and Board Review
Format: PDF / Kindle (mobi) / ePub
800 Q&A deliver a rigorous review for pulmonary board certification
Part of the acclaimed McGraw-Hill Education Specialty Board Review series, this well-illustrated review is essential for pulmonary medicine physicians preparing for board certification or recertification. The coverage mirrors the board exam outline of the American Board of Internal Medicine (ABIM), focusing specifically on the most commonly tested topics in obstructive lung disease, critical care, diffuse parenchymal lung disease, sleep medicine, infections, and neoplasms.
Offering more illustrations than similar reviews, Pulmonary Disease Examination and Board Review delivers authoritative coverage of the key concepts tested on the certification exam, including: making a diagnosis, test ordering and interpretation, treatment recommendations, understanding epidemiologic studies, understanding pathophysiology, and applying basic science knowledge to clinical situations.
- Case-based presentation mirrors the exam format
- Includes numerous high-quality images, including: x-rays, CT scans, and electrocardiograms
- Excellent as clinical refresher in pulmonary medicine
better or the microdebrider group, achieving superior postoperative voice outcomes. CASE 6 Question 1: D. Fibrinous exudates with septate hyphae branching at 45 degrees T e patient presents with recurrent respiratory tract in ection symptoms, but o particular note is her productive cough o gelatinous material. T e C scan shows an obstructing mass-like lesion, with a bronchoscopic examination demonstrating a thick exudative material, which appears to be nonadherent to the walls o the airway. T
at 12 weeks and 24 weeks respectively, combination varenicline and a nicotine patch versus varenicline alone.20 More largescale clinical trials are needed along with meta-analysis data to ensure there is in act an increased abstinence rate exists with combination therapy. CASE 3 Question 1: B. As soon as she is discharged T e Joint Committee o American T oracic Society and the European Respiratory Society def nes “pulmonary rehabilitation is a comprehensive intervention based on a thorough
been. In addition, anxiety is a known risk actor in emale COPD patients, however given this patient is a male, anxiety does not play a role. Irritable Bowel Syndrome is not a known risk actor in the CO E index. T e BODE index does not account or comorbid conditions in COPD. T e BODE index utilizes our actors, including BMI (B), FEV1—which quantif es the degree o airway obstruction (O), patient’s perceived level o dyspnea (D), and patient’s exercise capacity—using a 6-minute walk test (E). CASE 6
dose can be increased as long as oral steroids are added. CASE 6 An 18-year-old pregnant woman, 14 weeks age o gestation, is re erred to you by her obstetrician as she states she has a history o wheezing and shortness o breath as a child and currently gets woken up by her symptoms once a week. Her pulmonary unction tests show reversible air ow obstruction characteristic o asthma. She is a raid o taking any medications as she thinks it will harm her baby. Question 1: You give her a script or a
temporal heterogeneity, broblastic oci and absent acute lung injury, eosinophils and granulomas. ** Chronic hypersensitivity pneumonitis (CHP) is a parenchymal lung disease rom an inhalation exposure, with occasional positive serum precipitations and compatible clinical, radiographic, and physiologic ndings. Radiographically, it might be di cult to distinguish CHP rom brotic NSIP and UIP; although the presence o centrilobular nodules, lobular areas with decreased attenuation and vascularity, and